Clinical Trial Update: Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating trastuzumab plus pertuzumab (QL1209) with docetaxel in early-stage or locally advanced HER2-positive, ER/PR-negative breast cancer; tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• QL1209 (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED